1st May 2007
National Institute for Health and Clinical Excellence (NICE)
Summary

Source: National Guidelines Clearinghouse

GUIDELINE OBJECTIVE(S)

To assess the clinical and cost-effectiveness of cardiac resynchronisation therapy for people with heart failure and evidence of dyssynchrony by comparing cardiac resynchronisation therapy with a pacing device (CRT-P) and cardiac resynchronisation therapy with a defibrillator device (CRT-D) each with optimal pharmacological therapy (OPT) and each other

TARGET POPULATION

Patients with heart failure

INTERVENTIONS AND PRACTICES CONSIDERED

1. Cardiac resynchronisation therapy with a pacing device (CRT-P)
2. Cardiac resynchronisation therapy with a defibrillator device (CRT-D)

MAJOR OUTCOMES CONSIDERED

• Clinical effectiveness
  • Mortality (all cause, cardiac-related, sudden death, and non-cardiac death)
  • Morbidity (heart failure hospitalization, worsening heart failure, and arrhythmias)
  • New York Heart Association (NYHA) class
  • Exercise capacity
  • Adverse events
  • Health-related quality of life
• Cost-effectiveness